Last reviewed 2026-04-22 · How we verify

Minocycline (yes/no)

Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Minocycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Used for Bacterial infections (acne, respiratory tract infections, urinary tract infections, rickettsial infections), Rheumatoid arthritis (off-label use based on anti-inflammatory properties).

At a glance

Mechanism of action

Minocycline blocks bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from entering the A site of the ribosome. This broad-spectrum tetracycline antibiotic is effective against many gram-positive and gram-negative bacteria, as well as some atypical organisms. It also has anti-inflammatory and neuroprotective properties that extend beyond its antimicrobial effects.

Approved indications

• Bacterial infections (acne, respiratory tract infections, urinary tract infections, sexually transmitted infections)
• Rheumatoid arthritis (off-label use based on anti-inflammatory properties)

Common side effects

• Photosensitivity
• Nausea and vomiting
• Dizziness or vertigo
• Esophageal irritation
• Vaginal candidiasis
• Pigmentation changes

Key clinical trials

• Minocycline Administration During Human Liver Transplantation (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Minocycline (yes/no) CI brief — competitive landscape report
• Minocycline (yes/no) updates RSS · CI watch RSS
• Medical University of South Carolina portfolio CI